Patient info Open main menu

Everolimus Mylan 2.5 mg tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine strength:
2.5 mg
Contains active substance:
ATC code:
Similar medicines:

Patient leaflet - Everolimus Mylan 2.5 mg tablets

1 What Everolimus Mylan is and what it is used for

Everolimus Mylan is an anticancer medicine containing the active substance everolimus. Everolimus reduces the blood supply to the tumour and slows down the growth and spread of cancer cells.

Everolimus Mylan is used to treat adult patients with:

  • hormone receptor-positive advanced breast cancer in postmenopausal women, in whom other treatments (so called “non-steroidal aromatase inhibitors”) no longer keep the disease under control. It is given together with a medicine called exemestane, a steroidal aromatase inhibitor, which is used for hormonal anticancer therapy.
  • advanced tumours called neuroendocrine tumours that originate from the stomach, bowels, lung or pancreas. It is given if the tumours are inoperable and do not overproduce specific hormones or other related natural substances.
  • advanced kidney cancer (advanced renal cell carcinoma), where other treatments (so-called “VEGF-targeted therapy”) have not helped stop your disease.

2 What you need to know before you take Everolimus Mylan

Everolimus Mylan will only be prescribed for you by a doctor with experience in cancer treatment. Follow all the doctor’s instructions carefully. They may differ from the general information contained in this leaflet. If you have any questions about Everolimus Mylan or why it has been prescribed for you, ask your doctor.

Do not take Everolimus Mylan:

  • if you are allergic to everolimus, to related substances such as sirolimus or temsirolimus, or to any of the other ingredients of this medicine (listed in section 6).

If you think you may be allergic, ask your doctor for advice.

Warnings and precautions

Talk to your doctor before taking Everolimus Mylan:

  • if you have any problems with your liver or if you have ever had any disease which may have affected your liver. If this is the case, your doctor may need to prescribe a different dose of Everolimus Mylan.
  • if you have diabetes (high level of sugar in your blood). Everolimus Mylan may increase blood sugar levels and worsen diabetes mellitus. This may result in the need for insulin and/or oral antidiabetic agent therapy. Tell your doctor if you experience any excessive thirst or increased frequency of urination.
  • if you need to receive a vaccine while taking Everolimus Mylan.
  • if you have high cholesterol. Everolimus Mylan may elevate cholesterol and/or other blood fats.
  • if you have had recent major surgery, or if you still have an unhealed wound following surgery. Everolimus Mylan may increase the risk of problems with wound healing.
  • if you have an infection. It may be necessary to treat your infection before startingEverolimus Mylan.
  • if you have previously had hepatitis B, because this may be reactivated during treatment with Everolimus Mylan (see section 4 ‘Possible side effects’).
  • if you have received or are about to receive radiation therapy.

Everolimus Mylan may also:

  • weaken your immune system. Therefore, you may be at risk of getting an infection while you are taking Everolimus Mylan. If you have fever or other signs of an infection, consult with your doctor. Some infections may be severe and may have fatal consequences.
  • impact your kidney function. Therefore, your doctor will monitor your kidney function while you are taking Everolimus Mylan.
  • cause shortness of breath, cough and fever.
  • cause mouth ulcers and sores to develop. Your doctor might need to interrupt or discontinue your treatment with Everolimus Mylan.You might need treatment with a mouthwash, gel or other products. Some mouthwashes and gels can make ulcers worse, so do not try anything without checking with your doctor first. Your doctor might restart treatment with Everolimus Mylan at the same dose or at a lower dose.
  • cause complications of radiation therapy. Severe complications of radiotherapy (such as shortness of breath, nausea, diarrhoea, skin rashes and soreness in mouth, gums and throat), including fatal cases, have been observed in some patients who were taking everolimus at the same time as radiation therapy or who were taking everolimus shortly after they had radiation therapy. In addition, so-called radiation recall syndrome (comprising skin redness or lung inflammation at the site of previous radiation therapy) has been reported in patients who had radiation therapy in the past.

    Tell your doctor if you are planning to have radiation therapy in the near future, or if you have had radiation therapy before.

  • -

Tell your doctor if you experience these symptoms.

You will have regular blood tests during treatment. These will check the amount of blood cells (white blood cells, red blood cells and platelets) in your body to see if Everolimus Mylan is having an unwanted effect on these cells. Blood tests will also be carried out to check your kidney function (level of creatinine) and liver function (level of transaminases) and your blood sugar and cholesterol levels. This is because these can also be affected by Everolimus Mylan.

Children and adolescents

Everolimus Mylan is not to be used in children or adolescents (age below 18 years).

Other medicines and Everolimus Mylan

Everolimus Mylan may affect the way some other medicines work. If you are taking other medicines at the same time as Everolimus Mylan your doctor may need to change the dose of Everolimus Mylan or the other medicines.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

The following may increase the risk of side effects with Everolimus Mylan:

  • ketoconazole, itraconazole, voriconazole, or fluconazole and other antifungals used to treat fungal infections.
  • clarithromycin, telithromycin or erythromycin, antibiotics used to treat bacterial infections.
  • ritonavir and other medicines used to treat HIV infection/AIDS.
  • verapamil or diltiazem, used to treat heart conditions or high blood pressure.
  • dronedarone, a medicine used to help regulate your heart beat.
  • ciclosporin, a medicine used to stop the body from rejecting organ transplants.
  • cannabidiol (uses amongst others include treatment of seizures).
  • imatinib, used to inhibit the growth of abnormal cells.
  • angiotensin-converting enzyme (ACE) inhibitors (such as ramipril) used to treat high blood pressure or other cardiovascular problems.
  • nefazodone, used to treat depression.

The following may reduce the effectiveness of Everolimus Mylan:

  • rifampicin, used to treat tuberculosis (TB).
  • efavirenz or nevirapine, used to treat HIV infection/AIDS.
  • St. John’s wort (Hypericum perforatum), a herbal product used to treat depression and other conditions.
  • dexamethasone, a corticosteroid used to treat a wide variety of conditions including inflammatory or immune problems.
  • phenytoin, carbamazepine or phenobarbital and other anti-epileptics used to stop seizures or fits.

These medicines should be avoided during your treatment with Everolimus Mylan. If you are taking any of them, your doctor may switch you to a different medicine, or may change your dose of Everolimus Mylan.

Everolimus Mylan with food and drink

Avoid grapefruit and grapefruit juice while you are on Everolimus Mylan. It may increase the amount of [Product name] in the blood, possibly to a harmful level.

Pregnancy, breast-feeding and fertility

Pregnancy

Everolimus Mylan could harm your unborn baby and is not recommended during pregnancy. Tell your doctor if you are pregnant or think that you may be pregnant. Your doctor will discuss with you whether you should take this medicine during your pregnancy.

Women who could potentially become pregnant should use highly effective contraception during treatment and for up to 8 weeks after ending treatment. If, despite these measures, you think you may have become pregnant, ask your doctor for advice before taking any more Everolimus Mylan.

Breast-feeding

Everolimus Mylan could harm yourbreast-fed baby. You should not breast-feed during treatment and for 2 weeks after the last dose of everolimus. Tell your doctor if you are breast-feeding.

Female fertility

Absence of menstrual periods (amenorrhoea) has been observed in some female patients receiving Everolimus Mylan.

Everolimus Mylan may have an impact on female fertility. Talk to your doctor if you wish to have children.

Male fertility

Everolimus Mylan may affect male fertility. Talk to your doctor if you wish to father a child.

Driving and using machines

If you feel unusually tired (fatigue is a very common side effect), take special care when driving or using machines.

Everolimus Mylan contains lactose

[Product name] contains lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

3 How to take Everolimus Mylan

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is 10 mg, taken once a day. Your doctor will tell you how many tablets of Everolimus Mylan to take.

If you have liver problems, your doctor may start you on a lower dose of Everolimus Mylan (2.5, 5 or 7.5 mg per day).

If you experience certain side effects while you are taking Everolimus Mylan (see section 4), your doctor may lower your dose or stop treatment, either for a short time or permanently.

Take Everolimus Mylan once a day, at about the same time every day, consistently either with or without food.

Swallow the tablet(s) whole with a glass of water. Do not chew or crush the tablets.

If you take more Everolimus Mylan than you should

  • If you have taken too much Everolimus Mylan, or if someone else accidentally takes your tablets, see a doctor or go to a hospital immediately. Urgent treatment may be necessary.
  • Take the carton and this leaflet, so that the doctor knows what has been taken.

If you forget to take Everolimus Mylan

If you miss a dose, take your next dose as scheduled. Do not take a double dose to make up for the forgotten tablets.

If you stop taking Everolimus Mylan

Do not stop taking Everolimus Mylan unless your doctor tells you to.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4 Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

STOP taking Everolimus Mylan and seek medical help immediately if you experience any of the following signs of an allergic reaction:

  • difficulty breathing or swallowing
  • swelling of the face, lips, tongue or throat
  • severe itching of the skin, with a red rash or raised bumps.

Serious side effects of Everolimus Mylan include:

Very common (may affect more than 1 in 10 people)

  • Increased temperature, chills (signs of infection)
  • Fever, coughing, difficulty breathing, wheezing (signs of inflammation of the lung, also known as pneumonitis).

Common (may affect up to 1 in 10 people)

  • Excessive thirst, high urine output, increased appetite with weight loss, tiredness (signs of diabetes)
  • Bleeding (haemorrhage), for example in the gut wall
  • Severely decreased urine output (sign of kidney failure).

Uncommon (may affect up to 1 in 100 people)

  • Fever, skin rash, joint pain and inflammation, as well as tiredness, loss of appetite, nausea, jaundice (yellowing of the skin), pain in the upper right abdomen, pale stools, dark urine (may be signs of hepatitis B reactivation)
  • Breathlessness, difficulty breathing when lying down, swelling of the feet or legs (signs of heart failure)
  • Swelling and/or pain in one of the legs, usually in the calf, redness or warm skin in the affected area (signs of blockade of a blood vessel (vein) in the legs caused by blood clotting)
  • Sudden onset of shortness of breath, chest pain or coughing up blood (potential signs of pulmonary embolism, a condition that occurs when one or more arteries in your lungs become blocked)
  • Severely decreased urine output, swelling in the legs, feeling confused, pain in the back (signs of sudden kidney failure)
  • Rash, itching, hives
  • difficulty breathing or swallowing, dizziness (signs of serious allergic reaction, also known as hypersensitivity).

Rare (may affect up to 1 in 1,000 people)

  • Shortness of breath or rapid breath (signs of acute respiratory distress syndrome).

If you experience any of these side effects, tell your doctor immediately as this might have life-threatening consequences.

Other possible side effects of Everolimus Mylan include:

Very common (may affect more than 1 in 10 people)

  • Tiredness, breathlessness, dizziness, pale skin, signs of low level of red blood cells (anaemia)
  • High level of sugar in the blood (hyperglycaemia),
  • Loss of appetite,
  • High level of lipids (fats) in the blood (hypercholesterolaemia)
  • Disturbed taste (dysgeusia),
  • Headache
  • Nose bleeds (epistaxis)
  • Cough
  • Mouth ulcers
  • Upset stomach including feeling sick (nausea) or diarrhea
  • Skin rash,
  • Iitching (pruritus)
  • Feeling weak or tired,
  • Swelling of arms, hands, feet, ankles or other part of the body (signs of oedema)
  • Weight loss.

Common (may affect up to 1 in 10 people)

  • Spontaneous bleeding or bruising (signs of low level of platelets, also known as thrombocytopenia)
  • Fever, sore throat, mouth ulcers due to infections (signs of low level of white blood cells, leukopenia, lymphopenia and/or neutropenia)
  • Lymphoedema (swelling of body tissue, usually in the arms or legs)
  • Breathlessness (dyspnoea)
  • Thirst, low urine output, dark urine, dry flushed skin, irritability (signs of dehydration)
  • Trouble sleeping (insomnia)
  • Headache, dizziness (sign of high blood pressure, also known as hypertension)
  • Fever
  • Inflammation of the inner lining of the mouth, stomach, gut
  • Dry mouth
  • Heartburn (dyspepsia)
  • Being sick (vomiting)
  • Difficulty in swallowing (dysphagia)
  • •Abdominal pain
  • Acne
  • •Rash and pain on the palms of your hands or soles of your feet (hand-foot syndrome)
  • Reddening of the skin (erythema)
  • Joint pain
  • •Pain in the mouth
  • Menstruation disorders such as irregular periods
  • High level of lipids (fats) in the blood (hyperlipidaemia, raised triglycerides)
  • Low level of potassium in the blood (hypokalaemia)
  • Low level of phosphate in the blood (hypophosphataemia)
  • Low level of calcium in the blood (hypocalcaemia)
  • Dry skin, skin exfoliation, skin lesions
  • Nail disorders, breaking of your nails
  • Mild loss of hair
  • Abnormal results of liver blood tests (increased alanine and aspartate aminotransferase)
  • Abnormal results of renal blood tests (increased creatinine)
  • Swelling of the eyelid
  • Protein in the urine.

Uncommon (may affect up to 1 in 100 people)

  • Weakness, spontaneous bleeding or bruising and frequent infections with signs such as fever, chills, sore throat or mouth ulcers (signs of low level of blood cells, also known as pancytopenia)
  • Loss of sense of taste (ageusia)
  • Coughing up blood (haemoptysis)
  • Menstruation disorders such as absence of periods (amenorrhoea)
  • Passing urine more often during daytime
  • Chest pain
  • Abnormal wound healing
  • Hot flushes
  • Discharge from the eye with itching and redness •pink eye or red eye (conjunctivitis).

Rare (may affect up to 1 in 1,000 people)

  • Tiredness, breathlessness, dizziness, pale skin (signs of low level of red blood cells, possibly due to a type of anaemia called pure red cell aplasia)
  • Swelling of the face, around the eyes, mouth, and inside the mouth and/or throat, as well as the tongue and difficulty breathing or swallowing (also known as angioedema), may be signs of an allergic reaction.

Not known (frequency cannot be estimated from the available data)

  • Reaction at the site of previous radiation therapy, e.g. skin redness or lung inflammation (so-called radiation recall syndrome)
  • Worsening of radiation treatment side effects

If these side effects get severe please tell your doctor and/or pharmacist. Most of the side effects are mild to moderate and will generally disappear if your treatment is interrupted for a few days.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Everolimus Mylan

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister foil. The expiry date refers to the last day of that month.

Store in the original package in order to protect from light.

This medicine does not require any special temperature storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6 Contents of the pack and other information

What Everolimus Mylan contains

  • The active substance is everolimus. Each tablet contains 2.5 mg, 5 mg or 10 mg everolimus.
  • The other ingredients are: butylhydroxytoluene (E321), hypromellose (E464), lactose, lactose monohydrate, crospovidone (E1202) and magnesium stearate (E470b). See section 2 ‘Everolimus Mylan contains lactose’.

What Everolimus Mylan looks like and contents of the pack

Everolimus tablets are available in three strengths:

Everolimus Mylan 2.5 mg tablets are white to off white oval biconvex tablets, debossed with E9VS on one side and 2.5 on the other side.

Everolimus Mylan 5 mg tablets are white to off white oval and biconvex tablets, debossed with E9VS 5 on one side.

Everolimus Mylan 10 mg tablets are white to off white oval and biconvex tablets, debossed with E9VS 10 on one side.

Everolimus Mylan 2.5 mg, Everolimus Mylan 5 mg, Everolimus Mylan 10 mg tablets are available in packs containing 30 or 90 tablets in blisters or containing 30 tablets in perforated unit-dose blisters.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Mylan

Potters Bar

EN6 1TL

United Kingdom

Manufacturer(s):

Synthon BV

Microweg 22

6545 CM Nijmegen

The Netherlands

Synthon Hispania SL Castelló 1, Polígono Las Salinas 08830 Sant Boi de Llobregat Spain

This medicinal product is authorised in the Member States of the EEA and in the United Kingdom (Northern Ireland) under the following names:

Netherlands: Everolimus Mylan 2,5 mg, 5 mg, 10 mg, tabletten

Austria: Everolimus Mylan 2,5 mg, 5 mg, 10 mg Tabletten

Bulgaria: Еверолимус Майлан 5 mg, 10mg таблетки

Croatia: Everolimus Mylan 2,5 mg, 5 mg, 10 mg tablete

Czech Republic: Everolimus Mylan

Denmark: Everolimus Mylan, 2,5 mg, 5 mg, 10 mg tabletter

Finland: Everolimus Mylan, 2,5 mg, 5 mg, 10 mg tabletti

France: Everolimus Mylan 2,5 mg, 5 mg, 10 mg comprimés

Germany: Everolimus Mylan 2,5 mg, 5 mg, 10 mg Tabletten

Italy: Everolimus Mylan, 2,5 mg, 5 mg, 10 mg -compresse

Portugal: Everolimus Mylan

Romania: Everolimus Mylan 2,5 mg, 5 mg, 10 mg comprimate

Spain: Everolimus Mylan 5 mg, 10 mg comprimidos EFG

Sweden: Everolimus Mylan, 2,5 mg, 5 mg, 10 mg tabletter

United Kingdom: Everolimus Mylan 2.5 mg, 5 mg, 10 mg tablets

This leaflet was last revised in September 2022

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 04569/1743

Last revision stated in the text: September 2022 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Everolimus Mylan 2.5 mg tablets

Active substance Everolimus
Strength 2.5 mg
Pharmaceutical form White to off white oval biconvex tablets (approximately 10 x 5 mm), debossed with E9VS on one side and 2.5 on the other side.
Excipients Butylhydroxytoluene (E321), Hypromellose (E464), Lactose, Lactose monohydrate, Crospovidone (E1202), Magnesium stearate (E470b)
Shelf life 3 years
Storage Store in the original package in order to protect from light.
This medicinal product does not require any special temperature storage conditions.
Drug group (ATC) Antineoplastic agents, other antineoplastic agents, protein kinase inhibitors
  1. L Antineoplastic and immunomodulating agents
    1. L01 Antineoplastic agents
      1. L01E Protein kinase inhibitors, antineoplastic and immunomodulating agents
        1. L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors
          1. L01EG02 everolimus
Marketing authorisation PL 04569/1743 (first authorised 28 May 2025)
Marketing authorisation holder Generics (UK) Ltd T/A Mylan

Sources: the MHRA product information (products.mhra.gov.uk). Contains public sector information licensed under the Open Government Licence v3.0.